Status:

APPROVED_FOR_MARKETING

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Lead Sponsor:

Taiho Oncology, Inc.

Conditions:

Advanced Cholangiocarcinoma

Eligibility:

All Genders

18+ years

Brief Summary

The objective of the study is to provide access to TAS-120 to patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements.

Detailed Description

This is an open-label study to provide expanded access to TAS-120 prior to its commercial availability for patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements who have failed...

Eligibility Criteria

Inclusion

  • Provide written informed consent.
  • \>18 years of age.
  • Histologically confirmed, locally advanced, or metastatic, or recurrent unresectable CCA harboring FGFR2 gene rearrangements based on testing performed by a qualified (CLIA-certified) laboratory.
  • Patient has failed standard therapy or standard therapy is not tolerated.
  • Has measurable or non-measurable lesion(s).
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Adequate organ function.

Exclusion

  • History and/or current evidence of non-tumor related alteration of calcium-phosphorus homeostasis.
  • History and/or current evidence of clinically significant ectopic mineralization/calcification.
  • History and/or current evidence of clinically significant retinal disorder confirmed by retinal examination.
  • A serious illness or medical condition(s)
  • Pregnant or breast-feeding female

Key Trial Info

Start Date :

Trial Type :

EXPANDED_ACCESS

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04507503

Last Update

January 7 2025

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

Banner MD Anderson

Gilbert, Arizona, United States, 85234

2

University of California, San Francisco (UCSF)

San Francisco, California, United States, 94143

3

UCLA Division of Hematology-Oncology

Santa Monica, California, United States, 90404

4

Mount Sinai Center of Florida

Miami Beach, Florida, United States, 33140

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | DecenTrialz